Oct. 22 at 3:55 PM
PRISM BioView Dive: Psychedelics are moving from counterculture to clinical credibility. With the market projected to hit
$11B by 2034, biotech leaders like
$MNMD,
$ATAI, and
$CMPS are redefining mental health through data-driven, AI-enhanced therapeutics.
https://prismmarketview.com/prism-bioview-dive-psychedelic-therapeutics-from-counterculture-to-clinical-breakthrough-heres-who-to-watch-once-dismissed-as-fringe-science-psychedelics-are-now-driving/